Drug Trial Radar · NCT07730281
PRA-216 COPD Safety and Biomarker Study
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 25, 2026
Primary completion
Jun 1, 2027
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Prana Therapies IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
PRA-216Drug
biologic
PlaceboDrug
matching placebo for PRA-216
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 40 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Emeritus Research Sydney
Botany, New South Wales, Australia · Recruiting
Campbelltown Hospital
Campbelltown, New South Wales, Australia · Not yet recruiting
University of the Sunshine Coast
Birtinya, Queensland, Australia · Recruiting
Griffith University
Southport, Queensland, Australia · Recruiting
Emeritus Research Camberwell
Camberwell, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.